Ultragenyx藥業 RARE 深 滬
交易中 02-04 09:48:01 美东时间
25.035
+0.235
+0.95%
華盛通- 最 高25.07
- 今 開25.07
- 成交量 1.30万股
- 最 低 25.03
- 昨 收 24.80
- 總市值 24.15亿
- 52周最高 45.00
- 市盈率 靜 --
- 換手率 0.01%
- 52周最低 18.41
- 委 比 93.54%
- 總股本 9647.76万
- 歷史最高 179.647
- 量 比 0.95
- 振 幅 0.16%
- 歷史最低 18.41
- 每 手 1
- 風險率 5.44%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 潜在涨幅213.87%！Wave Life Sciences获Canaccord Genuity升目标价至43美元，维持"买入"评级
今日重点评级关注：Canaccord Genuity：维持Wave Life Sciences Ltd."买入"评级，目标价从40美元升至43美元；花旗：维持Palantir Technologies"买入"评级，目标价从235美元升至260美元
今天 12:15
9 Analysts Have This To Say About Ultragenyx Pharmaceutical
Ratings for Ultragenyx Pharmaceutical (NASDAQ:RARE) were provided by 9 analysts...
今天 06:00
HC Wainwright & Co. Reiterates Buy on Ultragenyx Pharmaceutical, Maintains $60 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Buy and maintains $60 price target.
02-03 21:17
Ultragenyx Resubmits UX111 Gene Therapy for FDA Review
Ultragenyx Pharmaceutical ( ($RARE) ) has issued an update. On January 30, 2026...
01-30 22:22
Ultragenyx Misses Primary Endpoints in Phase III Orbit and Cosmic Studies
Ultragenyx Misses Primary Endpoints in Phase III Orbit and Cosmic Studies Ultragenyx Pharmaceutical Inc. recently announced topline results from its Phase III Orbit and Cosmic studies evaluating the effectiveness of setrusumab (UX143) for the treatment of Osteogenesis Imperfecta. The results, presen
01-26 15:28
Ultragenyx Grants 16,355 Restricted Stock Units to New Employees
Ultragenyx Grants 16,355 Restricted Stock Units to New Employees Ultragenyx Pharmaceutical Inc. has granted 16,355 restricted stock units of its common stock to nine newly hired non-executive officers. The awards were made under the Ultragenyx Employment Inducement Plan, with the grant date set as J
01-26 15:25
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Pharmaceutical Inc. granted 16,355 restricted stock units to nine newly hired non-executive officers, vesting over four years. The company focuses on developing therapies for rare and ultra-rare diseases, driven by a strategy emphasizing efficient drug development to address high unmet medical needs.
01-23 21:30
Ultragenyx Pharmaceutical shares are trading higher after the company reported preliminary FY25 revenue results.
Ultragenyx Pharmaceutical shares are trading higher after the company reported ...
01-13 03:44
Mereo BioPharma Provides Corporate Update
Mereo BioPharma provided updates on setrusumab for osteogenesis imperfecta (OI) and alvelestat for alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD), with cash runway extended to mid-2027. Setrusumab's Phase 3 Orbit and Cosmic studies did not meet primary endpoints but showed significant improvements in bone mineral density. Further analyses are ongoing. Alvelestat is advancing toward a Phase 3 pivotal study, with partnering discus...
01-12 13:00
Ultragenyx to Present at the 44th Annual J.P. Morgan Healthcare Conference
Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) announced that its CEO and President, Emil D. Kakkis, M.D., Ph.D., will present at the 44th Annual J.P. Morgan Healthcare Conference on January 12, 2026. The live and archived webcast will be available on the company’s website. Ultragenyx is a biopharmaceutical company focused on developing novel therapies for serious rare and ultra-rare genetic diseases. With a diverse portfolio of approved therapies...
01-07 21:05
